As we will discuss later, this further justified the development of synthetic GLP-1/glucagon co-agonists as promising weight loss therapeutics, particularly in the context of avoiding unwanted hyperglycaemia in obesity-associated type 2 diabetes. Here, GLP1R is linked to obesity due to melanocortin 4 receptor deficiency.